1. Home
  2. NLOP vs CCCC Comparison

NLOP vs CCCC Comparison

Compare NLOP & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NLOP

Net Lease Office Properties of Beneficial Interest

N/A

Current Price

$13.91

Market Cap

198.4M

Sector

N/A

ML Signal

N/A

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

N/A

Current Price

$3.27

Market Cap

185.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NLOP
CCCC
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.4M
185.1M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
NLOP
CCCC
Price
$13.91
$3.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$46.00
$12.20
AVG Volume (30 Days)
316.9K
2.3M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
46.97%
N/A
EPS Growth
N/A
16.45
EPS
N/A
N/A
Revenue
$118,915,000.00
$35,947,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.02
52 Week Low
$12.76
$1.09
52 Week High
$34.53
$3.64

Technical Indicators

Market Signals
Indicator
NLOP
CCCC
Relative Strength Index (RSI) 31.73 72.92
Support Level $12.76 $1.96
Resistance Level $20.22 N/A
Average True Range (ATR) 0.52 0.30
MACD 0.17 0.09
Stochastic Oscillator 68.74 96.28

Price Performance

Historical Comparison
NLOP
CCCC

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: